Hikma Pharmaceuticals PLC - Back to Homepage

Keep yourself updated about Hikma

News Search

Search for a news item according to period of time or category.

Ensuring the Sustainability of our Business

Download Hikma's latest CR Report

11 November 2014

Hikma Celebrates the Lives of Cancer Survivors

Amman, 11 November 2014 - Hikma Pharmaceuticals, Jordan’s leading pharmaceutical manufacturer, continued in its annual Breast Cancer campaigns to increase awareness of the disease, in partnership with the Jordan Breast Cancer Program (JBCP), where this year’s campaign, an honorary celebration was organized for survivors at Wild Jordan Restaurant. The activity was dedicated to early detection, awareness of the disease as well personal stories of breast cancer survivors.

Amman, 11 November 2014 - Hikma Pharmaceuticals, Jordan’s leading pharmaceutical manufacturer, continued in its annual Breast Cancer campaigns to increase awareness of the disease, in partnership with the Jordan Breast Cancer Program (JBCP), where this year’s campaign, an honorary celebration was organized for survivors at Wild Jordan Restaurant. The activity was dedicated to early detection, awareness of the disease as well personal stories of breast cancer survivors.

Ten cancer survivors shared their stories with Hikma employees and talked about how they can lead an active and healthy life. “Having breast cancer is not a limitation, in my case, it was an opportunity to discover the hidden potential in me to develop my life and explore new horizons that I wouldn’t have thought before,” explained one of the survivors.

Ms. Hana Darwazah Ramadan, Vice President of Corporate Communication at Hikma Pharmaceuticals, said, “One of Hikma Pharmaceuticals’ corporate responsibility pillars is to positively influence and improve the livelihood of the society. Our health awareness campaigns complement our business objective of providing high quality medication and support our efforts towards a healthier society”. 

Hikma has invested heavily in developing capabilities for the manufacturing of oncology products; these investments include the acquisition of Thymoorgan in Germany, a joint venture with Haosun in China and the recent establishment of the oncology production facility in the chemicals plant in Jordan.

Press Release
+ more
Print page

CR

06 November 2014

Board Appointment – Dr Pamela Kirby

London, 6 November 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (OTC: HKMPY) ("Hikma"), the FTSE 250 pharmaceuticals company, is today announcing the appointment of Dr Pamela Kirby as an independent non-executive director of the Company with effect from 1 December 2014.

London, 6 November 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (OTC: HKMPY) ("Hikma"), the FTSE 250 pharmaceuticals company, is today announcing the appointment of Dr Pamela Kirby as an independent non-executive director of the Company with effect from 1 December 2014. Dr Kirby will join the Audit, Remuneration and Compliance, Responsibility and Ethics (CRE) Committees.

Said Darwazah, Chairman and Chief Executive, said: "I am delighted that Dr Kirby has agreed to join our Board. She brings a wealth of pharmaceutical, international, strategic, and listed company experience. She has a strong track record from her senior executive and board-level roles, and complements our culture and style perfectly. I am confident that she will enhance the capabilities of the Board, and that we are now in an even stronger position to lead our company going forward."

Dr Pamela Kirby
Dr Pamela Kirby was CEO of Quintiles Transnational Corp and has held senior executive positions in F Hoffmann-La Roche Ltd and AstraZeneca plc. Dr Kirby has chaired Oxford Immunotec Ltd and was senior independent director of Informa plc. Dr Kirby has previously held non-executive director positions with Smith & Nephew plc, Novo Nordisk A/S, Curalogic A/S and Oscient Pharmaceuticals Corp.

Dr Kirby is chairman of Scynexis Inc and a non-executive director of DCC plc and Victrex plc.

Dr Kirby holds a first-class Bachelor of Science degree in Pharmacology and a PhD in Clinical Pharmacology from the University of London.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, Vice President for Investor Relations +44 (0)20 7399 2760
Financial Dynamics
Matthew Cole & Ben Atwell +44 (0)20 3727 1000

Notes to Editors:

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

06 November 2014

Interim Management Statement

London, 6 November 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, is today updating the market on its current trading and financial position. This constitutes its Interim Management Statement relating to the period from 1 July 2014 to date, as required by the UK Listing Authority’s Disclosure and Transparency Rules.

London, 6 November 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, is today updating the market on its current trading and financial position. This constitutes its Interim Management Statement relating to the period from 1 July 2014 to date, as required by the UK Listing Authority’s Disclosure and Transparency Rules.

We are pleased to raise our guidance for 2014 to Group revenue growth of around 7%.

Injectables

Our global Injectables business is performing well, as we continue to capture specific market opportunities in the US. Competition is increasing in the US and we expect underlying sales in the second half to be broadly in line with the first half of the year. In MENA, we are seeing a good performance and are on track to deliver slight growth for the full year, while European contract manufacturing sales remain lower this year. Due to the continued strength of specific market opportunities, we are raising our guidance to around 25% revenue growth in 2014, with an adjusted operating margin of above 35%.

Following our acquisition of Bedford Laboratories in July, we also completed the acquisition of the Ben Venue manufacturing site in Bedford, Ohio in September. This will significantly enhance our R&D capabilities and enable us to expand future capacity for injectables manufacturing.

As previously announced, in October 2014 we received a warning letter from the US Food and Drug Administration ("FDA") related to the inspection of our manufacturing facility in Portugal in March 2014. We will work with the FDA to fully resolve all outstanding issues as quickly as possible.

Branded

Revenue in our Branded business is broadly in line with last year. We are delivering good growth in markets such as Egypt and the Gulf Cooperation Council ("GCC") countries, including Saudi Arabia, driven by our strategic focus on newer, higher value products. However, this is being offset by the ongoing restructuring of our business in Algeria and political disruptions, primarily in Iraq and Libya. Overall, we continue to expect the Branded business to deliver low single digit revenue growth for the full year, with an adjusted operating margin of around 21%.

Generics

The Generics business continues to perform very strongly this year, reflecting specific market opportunities and the re-introduction of products. We now expect the Generics business to deliver revenue of around $215 million in 2014, with an adjusted operating margin of around 55%.

On 30 September 2014, we received an approval for a New Drug Application for colchicine 0.6mg capsules by the US FDA, under Section 505(b)(2) of the US Federal Food Drug and Cosmetic Act. On 9 October, the US District Court for the District of Delaware granted Takeda Pharmaceuticals U.S.A., Inc. ("Takeda") a temporary restraining order while the court considered a motion by Takeda for a preliminary injunction. On 5 November, the court denied Takeda's motion but extended the temporary restraining order pending appeal. Our guidance for 2014 does not reflect any contribution from colchicine.

Financing position

Our financing position remains very strong and will enable us to make further strategic acquisitions and investments, as opportunities arise.

Said Darwazah, Chairman and Chief Executive Officer of Hikma said:

“I am pleased with how our businesses are performing this year. The continued strength of our Injectables business reflects the benefit of our broad portfolio and our success in capturing market opportunities. The Generics business continues to perform extremely well this year and we are focused on developing our portfolio and pipeline to support future growth. The Branded business is delivering good growth in a number of important markets and we believe the actions we are taking to restructure our business in Algeria and our commitment to operating in markets impacted by political disruptions, will strengthen our business for the future. ”

Hikma will announce its results for the year ending 31 December 2014 on 11 March 2015.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 20 7399 2760/
+44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations +44 20 7399 2765/
+44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

23 October 2014

Hikma Meet the Management Day London

London, 23 October 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, will host a Meet the Management Day in London on Tuesday 2 December 2014.

London, 23 October 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, will host a Meet the Management Day in London on Tuesday 2 December 2014.

The event will take place at The Westbury Hotel, 2nd Floor Westbury Gallery, Bond Street, London, W1S 2YF from 9.30am through to 2.30pm.

Our confirmed Management for the event are listed below. Hikma Management will be spread out across 4 meeting rooms and investors & analysts will rotate rooms to meet everyone in 4 Q&A slots.

Corporate Focus:
Said Darwazah, Chairman & CEO
Bassam Kanaan, Chief Strategy & Corporate Development Officer
Khalid Nabilsi, CFO

MENA Focus:
Mazen Darwazah, President & CEO MENA and Emerging Markets
Salah Mawajdah, Head of MENA
Hassan Shafiq, Managing Director, Hikma Egypt
Basel Ziyadeh, General Manager / GCC
Ma'moon Araidah, Senior Director of Sales & Marketing / MENA

US Generics Focus:
Mike Raya, CEO West-Ward Pharmaceuticals
Brian Hoffman, VP Corporate Development West-Ward Pharmaceuticals
Fadi Nassar, Corporate VP API
Spiro Gavaris, VP Sales and Marketing West-Ward Pharmaceuticals

Injectables Focus:
Riad Mishlawi, Vice President & Global Head of Injectables
Bashar Shomali, Vice President EU and Global Injectables
Natheer Masarweh, VP Quality Global Injectables and Operations (Portugal)

If you are interested in attending this event please contact Kate Komornicka kate@hikma.uk.com to register your interest and for further details.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Head of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

18 October 2014

Hikma Pharmaceuticals Launches ‘You Are Hikma’ 2014 Campaign

Amman, October 2014 – Hikma Pharmaceuticals, Jordan’s leading pharmaceutical manufacturer, held its annual employee welfare week “You Are Hikma” campaign to boost health and workplace safety. This year’s campaign under the slogan “Let’s work together for a safer and greener environment” was conducted at Hikma Pharmaceuticals headquarters in Amman, and at its subsidiary the Arab Pharmaceuticals Manufacturing company (APM) in Salt.

Amman, October 2014 – Hikma Pharmaceuticals, Jordan’s leading pharmaceutical manufacturer, held its annual employee welfare week “You Are Hikma” campaign to boost health and workplace safety. This year’s campaign under the slogan “Let’s work together for a safer and greener environment” was conducted at Hikma Pharmaceuticals headquarters in Amman, and at its subsidiary the Arab Pharmaceuticals Manufacturing company (APM) in Salt.

An international initiative staged at Hikma locations worldwide, ‘You Are Hikma’ celebrates the company’s core values by raising awareness among its staff on health, safety and environmental issues. With more than 350 participants, the campaign this year included a range of activities such as medical testing for the employees, blood drive, awareness lectures on work-related injuries, proper use of antibiotics, safe use of drugs, safe handling of materials and forklift training. Moreover, Hikma employees participated in the “Clean Up the World” activity of the Royal Society for the Conservation of Nature (RSCN), which took place in Dibeen Forest on October 18.

Hana Ramadan, Vice President of Corporate Communication at Hikma Pharmaceuticals, said, “‘You Are Hikma’ falls within the umbrella of Hikma’s corporate responsibility strategy that revolves around two major themes: Education and Well-Being. It emphasizes who we are as an organisation – ethical in our operations and dedicated to improving our employee’s quality of life and personal empowerment, through positive and valuable educational and environmental activities”.

+ more
Print page

CR

13 October 2014

Hikma enters partnership with Eisai for distribution of first-in-class epilepsy treatment Fycompa® in Middle East

London, 13 October 2014– Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces a partnership with Eisai Co., Ltd. (“Eisai”) for the distribution of Fycompa® (perampanel), Eisai’s first-in-class epilepsy treatment, in the Middle East. The partnership will commence immediately, with perampanel launches throughout the region expected to follow in 2015. Perampanel is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.i

London, 13 October 2014 - Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces a partnership with Eisai Co., Ltd. (“Eisai”) for the distribution of Fycompa® (perampanel), Eisai’s first-in-class epilepsy treatment, in the Middle East. The partnership will commence immediately, with perampanel launches throughout the region expected to follow in 2015. Perampanel is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.i

Perampanel is the only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a protein in the brain which plays a critical role in the spread of seizures.ii This mechanism of action is different to other currently available AEDs. In addition, perampanel has the added benefit of convenient, once-daily dosing at bedtime.i

“We are committed to our partnership with Eisai, which supports our strategy of working with global partners to strengthen our product portfolio in growing therapeutic areas and to bring important treatment options to patients in the Middle East region,” commented Mazen Darwazah, Hikma Pharmaceutical’s Executive Vice Chairman and President and CEO of MENA and Emerging Markets.

“We are very pleased to announce the partnership with Hikma, who will leverage their strong presence in the Middle East to ensure that people throughout the region will soon be able to access our innovative epilepsy treatment Fycompa,” commented Gary Hendler, President & CEO, Eisai EMEA.

Epilepsy is one of the most common neurological conditions in the world.iii The successful treatment of partial onset seizures remains a significant challenge in some patients and the incidence of uncontrolled partial epilepsy remains high despite many AEDs. Currently, up to 40% of patients with newly diagnosed epilepsy will become refractory to treatment.iv

Countries covered by the five year partnership will include the Kingdom of Saudi Arabia, United Arab Emirates, Jordan, Kuwait, Bahrain, Oman, Qatar, Sudan, Iraq, Libya and Yemen. Perampanel was approved by the European Commission on 23 July 2012 and the United States Federal Drug Administration (FDA) on 22 October 2012. Discovered and developed by Eisai in Europe and Japan, perampanel is manufactured in the UK.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760
Lucinda Henderson, Deputy Investor Relations Director +44 (0)20 7399 2765
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

 

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Product

08 October 2014

Hikma awarded Global Generics Company of the Year for EMEA

London, 8 October 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group is pleased to announce that it was the recipient of the ‘Company of the Year, EMEA Award” at the Global Generics and Biosimilars Awards held in Paris on 7 October 2014.

London, 8 October 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group is pleased to announce that it was the recipient of the ‘Company of the Year, EMEA Award” at the Global Generics and Biosimilars Awards held in Paris on 7 October 2014. The award recognises excellent performance across a range of business activities and was won in strong competition against a number of leading EMEA pharmaceutical companies.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 7831 3113

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

30 September 2014

Hikma receives approval for colchicine 0.6mg capsules

London, 30 September 2014 – Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the approval of its New Drug Application (NDA) for colchicine 0.6mg capsules by the US Food and Drug Administration (FDA).

London, 30 September 2014 – Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the approval of its New Drug Application (NDA) for colchicine 0.6mg capsules by the US Food and Drug Administration (FDA). Hikma will market its colchicine under the brand name MITIGARE.

MITIGARE is indicated for prophylaxis of gout flares in adults. This NDA has been approved under Section 505(b)(2) of the US Federal Food Drug and Cosmetic Act.

Said Darwazah, Chairman and CEO of Hikma, said, "This approval demonstrates our strong regulatory capabilities and the successful execution of our strategy to develop a more differentiated product portfolio for the US market."

According to IMS Health, sales of colchicine in the US market were approximately $688 million for the 12 months ending August 2014.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 7831 3113

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

Get adobe reader Most computers will open PDF documents automatically, but you may need to download Adobe Reader.